글 수정하기
글쓴이
E-mail
Homepage
글제목
글
Your account's overdrawn <a href=" http://www.akeminaito.com/compositions.php?cid=best-finance-essay-writing-service ">online essay scholarships</a> Lilly earlier this year asked U.S. and European regulatorsto approve two new diabetes treatments. One, a once-weekly pillcalled dulaglutide that is a so-called GLP-1 agonist, wouldcompete with similar drugs sold by Novo Nordisk andBristol-Myers Squibb. Another, called empaglifozin, is amember of an emerging new family of oral treatments called SGLT2inhibitors that remove excess blood sugar through the urine.
비밀번호
(수정과 삭제시 필요!! )